Biogen Inc.’s sales beat expectations, a sign that the company’s Alzheimer’s drug is helping offset pressure on its multiple ...

By Mariam Sunny April 29 (Reuters) - Biogen beat first-quarter expectations on Wednesday, as stronger sales of its ...

The FDA is looking at a slew of label expansions this month, including one that could open up home-based treatments for Alzheimer’s disease.

Investors are still waiting to see whether Bristol Myers and Regeneron’s pipelines will deliver, while Biogen was lifted by ...

Key dosing differences between Eli Lilly’s Kisunla and Biogen’s Leqembi are about to come to a head in the Alzheimer's market ...

Biogen will stop selling its Alzheimer’s treatment Aduhelm, a drug once seen as a potential blockbuster that stumbled after its launch a few years ago. The drugmaker also said Wednesday that it will ...

Biogen beats Q1 earnings and revenue estimates, fueled by new drug growth, but cuts 2026 EPS outlook to reflect M&A costs.

Biogen (BIIB) stock is in focus as the company beats forecasts with its Q1 2026 financials and trims its full-year earnings ...

Leqembi slows cognitive decline by 34% after four years No new safety issues found over four-year study period FDA decision on injectable version expected by August 31 An injectable version of the ...

If Novo Nordisk A/S’s wildly popular weight-loss drug succeeds in a highly anticipated trial for Alzheimer’s disease, Biogen Inc.’s Chief Executive Officer Chris Viehbacher doesn’t see it as a ...